Synergistic Role between p53 and JWA: Prognostic and Predictive Biomarkers in Gastric Cancer

Expression of p53 appears to be correlated to prognosis in patients with malignancy, but its role in gastric carcinoma has remained controversial. Recently we reported that JWA, an ADP-ribosylation-like factor 6 interacting protein 5 (ARL6ip5), was both prognostic for overall survival and predictive for platinum-based treatment of gastric cancer. In this study, we aimed to investigate p53 expression as a prognostic and predictive marker in resectable gastric cancer, alone and in combination with JWA. Expression of p53 was examined in three large patient cohorts (total n = 1155) of gastric cancer. High expression of p53 was significantly correlated with unfavorable clinicopathologic parameters and decreased overall patient survival. Furthermore, patients with high p53 expression in tumors acquired remarkable survival benefit from adjuvant first-line platinum-based-chemotherapy. The synergy between p53 and JWA in predicting patient outcome was demonstrated, while no significantly elevated predictive value concerning chemotherapy was observed. Thus, p53 expression is a potent prognostic and predictive factor for resectable gastric cancer with adjuvant platinum-based chemotherapy. A combined effect of p53 with JWA as efficient prognostic indicators was found for the first time.

[1]  M. Go,et al.  Epigenetic inactivation of paired box gene 5, a novel tumor suppressor gene, through direct upregulation of p53 is associated with prognosis in gastric cancer patients , 2012, Oncogene.

[2]  Heng Zhu,et al.  Global tumor protein p53/p63 interactome , 2012, Cell cycle.

[3]  A. El‐Naggar,et al.  p53-mediated senescence impairs the apoptotic response to chemotherapy and clinical outcome in breast cancer. , 2012, Cancer cell.

[4]  Yan Zhou,et al.  Prognostic and Predictive Role of JWA and XRCC1 Expressions in Gastric Cancer , 2012, Clinical Cancer Research.

[5]  U. Moll,et al.  Links between mutant p53 and genomic instability , 2012, Journal of cellular biochemistry.

[6]  Z. Long,et al.  The Prognostic Significance of Apoptosis-Related Biological Markers in Chinese Gastric Cancer Patients , 2011, PloS one.

[7]  G. Melino.  p63 is a suppressor of tumorigenesis and metastasis interacting with mutant p53 , 2011, Cell Death and Differentiation.

[8]  A. El‐Naggar,et al.  Restoring expression of wild-type p53 suppresses tumor growth but does not cause tumor regression in mice with a p53 missense mutation. , 2011, The Journal of clinical investigation.

[9]  Karen H. Vousden,et al.  p53 and its mutants in tumor cell migration and invasion , 2011, The Journal of cell biology.

[10]  A. Thompson,et al.  p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients , 2011, Breast Cancer Research.

[11]  Y. Qi,et al.  Distinct p53 Gene Signatures Are Needed to Predict Prognosis and Response to Chemotherapy in ER-Positive and ER-Negative Breast Cancers , 2011, Clinical Cancer Research.

[12]  C. Coffill,et al.  The role of mutant p53 in human cancer , 2011, The Journal of pathology.

[13]  T. Hupp,et al.  Drug discovery and mutant p53. , 2010, Trends in cell biology.

[14]  X.-y. Xie,et al.  The Potential for Serum p53 to Predict the Response to Chemotherapy of Patients with Gastric Cancer , 2010, The Journal of international medical research.

[15]  J. Bourdon,et al.  p53 family members in cancer diagnosis and treatment. , 2010, Seminars in cancer biology.

[16]  Varda Rotter,et al.  When mutants gain new powers: news from the mutant p53 field , 2009, Nature Reviews Cancer.

[17]  M. Moehler,et al.  Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era , 2009, Current opinion in oncology.

[18]  K. Mimori,et al.  p53-Altered FBXW7 expression determines poor prognosis in gastric cancer cases. , 2009, Cancer research.

[19]  Gang Li,et al.  JWA regulates XRCC1 and functions as a novel base excision repair protein in oxidative-stress-induced DNA single-strand breaks , 2009, Nucleic acids research.

[20]  Yusuke Nakamura,et al.  Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer , 2008, Nature Genetics.

[21]  J. Ji,et al.  Adjuvant chemotherapy for gastric cancer or not: a dilemma? , 2008, Journal of the National Cancer Institute.

[22]  Carsten Denkert,et al.  Association of patterns of class I histone deacetylase expression with patient prognosis in gastric cancer: a retrospective analysis. , 2008, The Lancet. Oncology.

[23]  A. Børresen-Dale,et al.  A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients , 2008, Acta oncologica.

[24]  David Cunningham,et al.  East meets west in the treatment of gastric cancer. , 2007, The New England journal of medicine.

[25]  J. Bartek,et al.  DNA Damage Response as an Anti-Cancer Barrier: Damage Threshold and the Concept of 'Conditional Haploinsufficiency' , 2007, Cell cycle.

[26]  Frédérick A. Mallette,et al.  The DNA Damage Signaling Pathway Connects Oncogenic Stress to Cellular Senescence , 2007, Cell cycle.

[27]  Hai-rong Chen,et al.  JWA as a functional molecule to regulate cancer cells migration via MAPK cascades and F-actin cytoskeleton. , 2007, Cellular signalling.

[28]  R. Chen,et al.  Identification of JWA as a novel functional gene responsive to environmental oxidative stress induced by benzo[a]pyrene and hydrogen peroxide. , 2007, Free radical biology & medicine.

[29]  Q. Wei,et al.  Identification and Functional Characterization of JWA Polymorphisms and their Association with Risk of Gastric Cancer and Esophageal Squamous Cell Carcinoma in a Chinese Population , 2007, Journal of toxicology and environmental health. Part A.

[30]  Karen H. Vousden,et al.  p53 in health and disease , 2007, Nature Reviews Molecular Cell Biology.

[31]  Huan Yang,et al.  Aurora‐A induces cell survival and chemoresistance by activation of Akt through a p53‐dependent manner in ovarian cancer cells , 2006, International journal of cancer.

[32]  Takako Yamada,et al.  Prognostic significance of p53 mutation in suboptimally resected advanced ovarian carcinoma treated with the combination chemotherapy of paclitaxel and carboplatin. , 2006, Cancer letters.

[33]  A. Egashira,et al.  Overexpression of Hypoxia-Inducible Factor 1α and p53 Is a Marker for an Unfavorable Prognosis in Gastric Cancer , 2006, Clinical Cancer Research.

[34]  H. Höfler,et al.  Prognostic significance of p21WAF1/CIP1, p27Kip1, p53 and E-cadherin expression in gastric cancer , 2006, Journal of Clinical Pathology.

[35]  Z. Livneh,et al.  p53 and p21 regulate error-prone DNA repair to yield a lower mutation load. , 2006, Molecular cell.

[36]  C. Zou,et al.  JWA, a novel signaling molecule, involved in the induction of differentiation of human myeloid leukemia cells. , 2006, Biochemical and biophysical research communications.

[37]  A. Fersht,et al.  Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[38]  V. Rotter,et al.  The role of p53 in base excision repair following genotoxic stress. , 2003, Carcinogenesis.

[39]  W. Allum,et al.  Guidelines for the management of oesophageal and gastric cancer , 2002, Gut.

[40]  D. Carbone,et al.  Serum anti-p53 antibodies in gastric adenocarcinoma patients are associated with poor prognosis, lymph node metastasis and poorly differentiated nuclear grade , 1999, British Journal of Cancer.

[41]  E. Tokunaga,et al.  Prognostic value of p53 protein expression for patients with gastric cancer – a multivariate analysis , 1999, British Journal of Cancer.

[42]  T. Aiko,et al.  The new Japanese Classification of Gastric Carcinoma: Points to be revised , 1998, Gastric Cancer.

[43]  W. El-Deiry,et al.  p53 and chemosensitivity , 1996, Nature Medicine.

[44]  A. Jemal,et al.  Cancer statistics, 2012 , 2012, CA: a cancer journal for clinicians.

[45]  V. Rotter,et al.  Understanding wild-type and mutant p53 activities in human cancer: new landmarks on the way to targeted therapies , 2011, Cancer Gene Therapy.

[46]  David P. Lane,et al.  Translating p53 into the clinic , 2010, Nature Reviews Clinical Oncology.

[47]  A. Egashira,et al.  Overexpression of hypoxia-inducible factor 1alpha and p53 is a marker for an unfavorable prognosis in gastric cancer. , 2006, Clinical Cancer Research.

[48]  M. Lai,et al.  Exogenous mutant p53 DNA enhanced cisplatin-induced apoptosis in TSGH-8301 human bladder cancer cells. , 2000, Anticancer Research.

[49]  P. Riis.  [Health and disease]. , 1989, Ugeskrift for laeger.

[50]  N. Dubrawsky.  Cancer statistics , 2022 .